BAY 87-2243

Code: SML2384-25MG D2-231

Biochem/physiol Actions

BAY 87-2243 has a therapeutic effect on ferroptosis‐based cancer, hypoxic pancreatic cancer cells.

BAY 87-2243 is an orally active oxidative pho...


read more

Your Price
€371.70 25MG
€457.19 inc. VAT

Biochem/physiol Actions

BAY 87-2243 has a therapeutic effect on ferroptosis‐based cancer, hypoxic pancreatic cancer cells.

BAY 87-2243 is an orally active oxidative phosphorylation (OxPhos) inhibitor that potently suppresses hypoxia-induced HIF-1 activation (IC50 = 0.7 nM by HCT-116-based reporter assay; 24 h 1% O2) by selectively targeting mitochondrial complex I (IC50 = 10 nM using mitochondria from PC3; no inhibition of complex III), exhibiting antiproliferation activity in cancer cultures only in the absence of glucose (IC50 ~3 nM in H460 cultures with 10 mM galactose or lactate, >10 µM with 10 mM glucose). BAY 87-2243 selectively inhibits hypoxia-induced, but not hypoxia-independent, HIF-1α & HIF-2α upregulation and HIF-1 target genes expression in cultures (IC50 ≤10 nM/ADM, ANGPTL4, CA9 mRNA in H460 cells; IC50 = 2 nM/carbonic anhydrase 9 (CA9) protein in HCT116 cells) and effectively suppresses H460 xenograft tumor growth in mice via daily oral admiminstration in vivo (ED50 ~2 mg/kg).

assay≥98% (HPLC)
colorwhite to beige
formpowder
SMILES stringCC1=CC(C2=NC(C3=CC=C(OC(F)(F)F)C=C3)=NO2)=NN1CC4=CC(N5CCN(C6CC6)CC5)=NC=C4
solubilityDMSO: 2 mg/mL, clear
storage temp.2-8°C
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.